# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-11T21:07:39.921771

---

**Idea Fidelity**

The paper closely follows the original manifest. It focuses squarely on exploiting the PDUFA 300-day deadline bunching to infer causal effects on post-market safety, uses the FDA NME dataset linked to FAERS, and presents the bunching analysis, density test, OLS control comparison, and RD robustness that were promised. All key elements of the identification strategy—density manipulation, RD around day 300, and the notion that bunching creates quasi-random timing variation—are present. The only minor omission is a more explicit formal treatment of the “marginal” drugs in the bunching estimator framework (e.g., a formal COMPARISON between the counterfactual distribution and the bunched mass as in McCrary/bunching papers), but this does not detract materially from the fidelity.

**Summary**

The paper documents a dramatic spike in approvals at the FDA’s 300-day PDUFA standard-review deadline and uses it as quasi-experimental variation in review timing to assess safety. With 538 standard-review NMEs (1993–2024) linked to FAERS reports, the author shows that while bunched drugs have higher raw adverse event counts, the difference disappears after controlling for therapeutic class, approval year, orphan/accelerated status, and years on market; RD estimates at the cutoff are also imprecise and statistically insignificant. The main conclusion is that deadline-induced timing distortions do not appear to compromise post-market safety.

**Essential Points**

1. **Willy-nilly interpretation of the OLS “controls” estimation as causal:** The empirical design rests on the idea that the bunching provides exogenous variation, so the preferred specification should be the RD around day 300 (possibly supplemented with the bilateral comparisons in the bunching window). However, Table 3 relies heavily on an OLS comparison of bunched versus non-bunched drugs with controls, which is vulnerable to omitted variable bias even within the [250,400]-day window if, for example, industry submissions systematically differ on unobservables beyond therapeutic class and approval year. The author should either shrink the comparison window further and present the argument more explicitly, or show that the RD estimate (with its own power limitations) is consistent when controlling for covariates. Without this, the stated causal conclusion is not fully justified.

2. **Running variable manipulation threatens RD continuity/interpretation:** The density test confirms manipulation—expected under deadline pressure—but RD identification relies on the assumption that potential outcomes are smooth in the absence of treatment. If FDA reviewers can shift an approval from day 299 to 301 (and onto the treated side) without altering the underlying quality/complexity, then RD is valid, but the paper needs to make that case more rigorously. For instance, is there evidence that applications around day 300 are similar on lagged information (e.g., number of review cycles, number of review issues, initial Complete Response Letters)? In the absence of such evidence, the RD may compare drugs with systematically different review trajectories, undermining the causal interpretation.

3. **FAERS linkage sample selection and exposure measurement:** Only 312 of the 538 standard-review NMEs link to FAERS, which may induce sample-selection bias if linking success correlates with the running variable. The paper should provide a table showing linkage rates by review duration or bunching status, and ideally balance the sample to ensure the RD is not driven by a nonrandom subset. Additionally, adverse event counts are cumulative, so drugs approved earlier (more likely to bunch) have longer exposure. The controls for “years on market” in the OLS regressions are not fully transparent—are they linear, logged, or also in interaction with time? There is also a possibility of post-treatment bias if more successful drugs stay on the market longer. A more careful exposure adjustment (e.g., event rates per year or offset terms in the RD model) would strengthen the interpretation.

If the authors cannot resolve these issues, the paper should be rejected. At least the causal claims need clearer support.

**Suggestions**

1. **Refine the RD specification and reporting.**  
   - The current RD results (Column 4 of Table 3) are underpowered, partly because there are only 11 observations below 300 days with FAERS data. Consider expanding the running variable window to include a broader range while still maintaining local validity, maybe using higher-order polynomials or flexible local linear fits with more observations, and report the bandwidth selection from \texttt{rdrobust}.  
   - Incorporate covariates in the RD regressions (e.g., therapeutic class or approval year) to improve precision if the assumptions hold. While RD identification does not require covariates, adding them can reduce variance without bias if they are smooth at the cutoff.  
   - Present placebo RD plots (with 95% confidence intervals) showing the fitted lines separately on each side of 300 days for key outcomes; this visual evidence strengthens the continuity argument for both outcomes and covariates.

2. **Clarify the bunching estimator mechanics.**  
   - The paper refers to the excess mass at the deadline but never uses it to estimate a “treatment effect” on the marginal bunching drugs (as in classic bunching literature). Consider formally estimating the effect size using the “bunched mass” as an instrument for treatment exposure (two-stage approach) or explicitly discussing how the counterfactual distribution is constructed.  
   - If feasible, compute a “bunching ratio”–based estimate that isolates the marginal drugs most affected by the deadline and compare their outcomes to those just beyond the window. This would align more cleanly with the causal narrative and help readers see the structural connection between the institutional deadline and the empirical design.

3. **Address FAERS exposure and reporting biases more rigorously.**  
   - Replace or supplement cumulative counts with rate-based or time-standardized outcomes (e.g., reports per year on market or per million prescriptions if utilization data is available).  
   - At minimum, show that the results are robust to including log(years on market) or interacting time with approval era, since older drugs inherently accumulate more reports.  
   - Explore whether FAR’s reporting patterns differ systematically by whether the NDA was approved before or after the PDUFA deadline (e.g., average reporter type, proportion of manufacturer reports), which could indicate differential scrutiny rather than real safety differences.

4. **Reconsider the interpretation of the null effect.**  
   - The paper argues that the null suggests FDA manages deadline pressure without compromising safety. But an alternative interpretation is that FAERS and regulatory outcomes are insufficiently sensitive, or that post-market safety issues take longer to surface for bunched drugs. Acknowledge this and consider checking for lagged effects (e.g., do bunched drugs accumulate serious events at a faster rate in the first few years post-approval?).  
   - That would also address the “time on market” confounder more directly: maybe bunched drugs have more reports not because they’re older, but because their adverse event curve is steeper. Event-study graphs of cumulative adverse events over time (matched on approval year) would help.

5. **Strengthen the contrast with prior literature.**  
   - The paper cites Downing et al. (2017) and Hseih et al. (2008), but it would be helpful to more carefully distinguish the current approach (quasi-experimental variation) from prior work and to explain why previous findings might be spurious.  
   - Consider replicating the two-month window correlation within the current dataset and showing explicitly how the inclusion of controls (or the RD) changes the estimated effect, highlighting why the bunching strategy adds credibility.

6. **Discuss external validity and policy implications carefully.**  
   - The conclusion states that deadlines can coexist with thorough review, harkening to broader regulatory design. Qualify this by noting that the sample is limited to standard NMEs (excluding generics, biologics under different pathways, and priority reviews) and that the results speak to FDA behavior under PDUFA’s current structure; generalizing to other agencies or to accelerated pathways requires caution.  
   - Given that the policy debate often revolves around trade-offs between speed and thoroughness, consider discussing whether the FDA’s ability to hit the deadline without safety costs might depend on resource levels (PDUFA fees supporting staffing) or on the nature of current submissions (more targeted therapies). This would help policymakers interpret the findings in context.

7. **Improve data transparency and reproducibility.**  
   - Provide descriptive statistics for the FAERS-linked sample versus the full NME sample (e.g., by approval year, therapeutic class, review duration) to reassure readers that the linkage does not select on the running variable or outcome.  
   - If the data permit, append a table showing the list of drugs in the bunching window versus adjacent windows, their therapeutic classes, and whether they were linked to FAERS, so readers can assess selection and heterogeneity.  
   - Including code snippets or references to the scripts used for API queries (maybe in an online appendix) would align with AER: Insights’ emphasis on transparency.

In sum, the paper is close to being publishable but would benefit from deeper engagement with the RD identification, a clearer exposition of the bunching estimator, and stronger handling of FAERS-related biases. Clarifying these points would solidify the causal claim that PDUFA deadlines do not erode safety.
